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Sir,
We reported last year, in the British Journal of Cancer, in a series
of 59 metastatic colorectal cancer (MCRC) patients treated with
cetuximab-based chemotherapy (CT), that KRAS mutation was
highly predictive of treatment resistance and that progression-free
survival was significantly increased in wild-type KRAS compared
with mutant KRAS patients (Di Fiore et al, 2007). All the studies
published so far have unambiguously confirmed that the presence
of somatic KRAS mutation is indeed highly predictive of resistance
to anti-EGFR antibodies in MCRC patients (Lie `vre et al, 2006,
2008; Benvenuti et al, 2007; Frattini et al, 2007; Khambata-Ford
et al, 2007; De Roock et al, 2008). Moreover, a large randomised
controlled trial on panitumumab integrating KRAS genotyping has
recently shown that, among 208 patients receiving panitumumab, 0
out of 84 mutants and 21 out of 124 (17%) wild-type patients were,
respectively, responders (Amado et al, 2008). Therefore, KRAS
genotyping should now be performed on a routine basis in patients
with MCRC. In most of these studies, KRAS genotyping has been
performed on primary colorectal tumours, whereas anti-EGFR
antibodies are used to treat the metastatic disease. This strategy
might, at least in certain circumstances, present two limitations.
First, systematic KRAS genotyping in MCRC patients might be
hampered in the future, at least for some patients, by the difficulty
of obtaining tumour samples suitable for molecular analyses (and
this might limit the use of anti-EGFR antibodies). Second,
considering the genetic heterogeneity of colorectal cancers, the
absence of detectable KRAS mutations in the primary tumour
cannot formally exclude the presence of a KRAS mutation in
metastases. For these two reasons, we think that detection of KRAS
mutation in the blood of patients with MCRC may have a clinical
interest in the context of anti-EGFR therapies and we would like to
highlight in this letter the potential interest of such a strategy.
Although several studies have shown the presence of mutant DNA
in blood from patients with colorectal neoplasia, only positive
results are informative. Therefore, one should consider the
development of combined tests indicating in blood, first the
presence of tumour DNA, then the status of KRAS. In MCRC,
hypermethylated DNA can be used as a blood tumour molecular
marker. For instance, hypermethylation of the RASSF2 gene has
frequently been detected in colorectal adenoma and invasive
carcinoma (Park et al, 2007), and we found, in a series of 32
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Figure 1 Detection of methylated RASSF2A promoter in the primary
tumour (T), liver metastases (M) and plasma (P) from patients 1 and 2. For
patient 2, T1 and T2 correspond to the right and left colon adenocarcinoma,
respectively. Genomic DNA was modified by bisulphite treatment and
amplified with primers specific of the methylated RASSF2A promoter. M,
molecular marker; Un, unmethylated DNA used as a negative control; Met,
methylated DNA, used as a positive control. The arrows indicate the 110bp
amplified product (A). Detection of a KRAS mutation in the plasma from
patient 1. Two independent real-time PCRs were performed from DNA
extracted from plasma, in the presence and in the absence of a PNA specific of
the wild-type KRAS sequence. The presence of mutant DNA within the
sample is detected by a significant shift towards lower values of the cycle
threshold (Ct) when the PNA is added to the reaction. The upper and lower
panels correspond to the sequences of the amplified products obtained in the
absence and presence of the PNA, respectively. In the presence of the PNA,
only the mutant allele is amplified. The sequences correspond to the antisense
strand, the box marks codon 12 and the arrows the c.35G4Cm u t a t i o n( B).
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the tumours (unpublished results). In addition to RASSF2, other
targets may be used to ensure a sensitive detection of tumour
DNA, if RASSF2 is not found hypermethylated. For sensitive
detection on a routine basis of KRAS mutation, several methods,
shown to be more sensitive than conventional dye-labelled
dideoxynucleotide sequencing, are now available, such as, SNaP-
shot or PCR-LCR assays (Di Fiore et al, 2007), or allele-specific
real-time PCR (De Roock et al, 2008; Lie `vre et al, 2008). We used
this strategy of combined blood assays to analyse two patients who
received cetuximab-based CT, one responder and the other
showing a progressive disease after anti-EGFR therapy. We
screened the plasma of these patients for the presence of
methylated DNA, using a classical methyl-specific assay exploring
the RASSF2A promoter after bisulphite treatment, and then for the
presence of KRAS mutation using real-time PCR, performed in the
presence of a peptide nucleic acid (PNA) sequence specific for the
wild-type KRAS codons 12 and 13, which inhibits amplification
from the wild-type template. The first patient, a 67-year-old man,
received cetuximab and irinotecan regimens for a peri-hepatic
lymph node tumour recurrence 12 months after surgery for
liver metastases, and after 3 months, evaluation revealed
disease progression. In patient plasma collected before the
beginning of cetuximab CT, the combined assays revealed the
presence of hypermethylated RASSF2 (Figure 1A) and the presence
of mutant KRAS. Sequencing analysis of the PCR product
obtained in the presence of the PNA revealed the same KRAS
mutation (Figure 1B), as the one previously detected in the
colorectal tumour and liver metastases. The second patient, a 76-
year-old man, received, in second line, cetuximab plus irinotecan
CT for hepatic metastasis occurring 4 years after curative surgery
for a bifocal CRC adenocarcinoma, and this treatment
allowed control of the disease with the duration of response of
10 months. In this patient, the combined assays performed on
the plasma collected before cetuximab treatment showed the
presence of hypermethylated RASFF2A (Figure 1) but the absence
of mutant KRAS.
We therefore suggest that, in the forthcoming clinical trials
on anti-EGFR antibodies in MCRC, which integrate KRAS
genotyping, it is probably useful to collect blood samples
before treatment and that the clinical interest of such combined
blood tests, using the presence of hypermethylated DNA, as
tumour DNA marker, and a sensitive method for KRAS mutation
detection, should be evaluated on large series of MCRC patients.
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